Related by context. All words. (Click for frequent words.) 82 Initiate Phase 81 Randomized Phase 81 Pivotal Phase 76 Meets Primary Endpoint 76 multicenter Phase 76 placebo controlled Phase 75 Second Pivotal Phase 75 Commences Phase 75 Phase 2b Clinical Trial 75 Trial Evaluating 75 randomized controlled Phase 75 Study Evaluating 74 Successfully Completes Phase 74 Phase IIb Trial 74 Completes Patient Enrollment 74 Pivotal Phase III 74 registrational Phase 74 Confirmatory Phase 74 Oral Fingolimod 74 Initiates Phase 74 Randomized Double blind 73 phase Ib 73 Pivotal Phase II 73 Phase IIIb 73 Prospective Randomized 73 LUX Lung 73 Randomized Phase II 72 controlled multicenter Phase 72 Initiates Phase II 72 Commence Phase 72 Phase III Pivotal 72 Clinical Trial Results 72 Phase 2a Clinical Trial 72 HCV SPRINT 72 treatment naive genotype 72 dose escalation clinical 72 multicenter phase 72 Randomised 72 Placebo Controlled 72 Randomized phase 72 Phase III Clinical Trial 72 Phase 2b Trial 71 dose escalation Phase 71 Dose Escalation 71 Clinical Trial Evaluating 71 ongoing Phase 1b 71 Double Blind Placebo 71 Phase 1a clinical 71 novel VDA molecule 71 Pooled Analysis 71 blinded randomized placebo controlled 71 Dose Ranging Study 71 RECORD1 71 Phase III Trial 71 Combination REOLYSIN R 71 Hormone Refractory Prostate Cancer 71 Novel Oral 71 Aflibercept 71 PEG IFN 71 IMPACT DCM 71 AZX# Phase 71 including eniluracil ADH 71 Multicenter Phase 71 Elagolix 71 Safinamide 71 initiated Phase Ib 71 Tesetaxel 71 Randomized Double Blind 70 Phase 2b Study 70 BRIM2 70 orally inhaled migraine 70 Dose Ranging 70 Pharmacokinetic Study 70 Pivotal Trials 70 TLK# 70 fosbretabulin 70 Randomized Clinical Trial 70 include Phenoptin TM 70 treatment naïve genotype 70 Hsp# Inhibitor 70 Phase Ib II 70 Adjuvant Treatment 70 First Patient Dosed 70 Multiple Ascending Dose 70 MKC# MT 70 Metastatic Melanoma 70 humanized interleukin 6 70 multicenter Phase III 70 Phase 1b Clinical Trial 70 CCX# B 70 II Clinical Trial 70 Completes Enrollment 70 Phase IIA 70 Multicenter Randomized 70 Relapsing Multiple Sclerosis 70 Initiate Phase III 70 Controlled Trial 70 phase IIIb 70 pharmacokinetic PK study 70 label multicenter Phase 70 sodium glucose cotransporter 70 Pivotal Study 69 Phase Ib Clinical Trial 69 Randomized Double Blind Placebo 69 ACCLAIM COPD 69 systemic Phase 1b 69 Randomized Phase III 69 GOUT 69 BRIM3 69 R#/MEM # 69 Bosutinib 69 RE MODEL 69 oral prodrug 69 Phase III multicenter 69 Phase 2a Trial 69 Investigational Oral 69 Topline Results 69 Initiates Phase III 69 severe NCI Grades 69 Glufosfamide 69 Files IND 69 multicenter Phase II 69 Phase IIb Clinical Trial 69 Janus kinase 69 Antiviral Activity 69 APEX PD 69 Parathyroid Hormone 69 Suppl. 69 multicentre randomized 69 TRANSFORMS 69 NSABP B 69 Demonstrated Significant 69 Pivotal Trial 69 assessing T DM1 69 Phase III Clinical Trials 69 Diabetic Nephropathy 69 Testosterone MDTS ® 69 Phase IIa Clinical Trial 69 AAG geldanamycin analog 69 Initiates Enrollment 69 Intervention Effectiveness 69 Matrix Phase 2b 69 randomized multicenter 69 sodium thiosulfate STS 69 Bayer HealthCare Onyx Pharmaceuticals 69 Long Term Efficacy 69 mGluR5 negative 69 armodafinil Tablets C 69 Phase Ib clinical 69 Late Breaker 69 evaluating Vectibix 69 phase IIa clinical 69 multicentre randomized double 69 multicenter randomized placebo controlled 69 BENCHMRK 69 Phase 2a clinical 68 Luramist TM 68 Demonstrates Positive 68 Initiate Clinical Trial 68 fidaxomicin Phase 68 dependent kinase inhibitor 68 PDX pralatrexate 68 antibody blinatumomab MT#/MEDI-# 68 Plus Ribavirin 68 Cloretazine ® 68 dextromethorphan quinidine 68 SPRYCEL ® 68 Placebo controlled 68 PRE SURGE 68 JAK Inhibitor 68 By Denes Husty 68 REG2 68 Dual Opioid 68 Randomized Clinical Trials 68 Preclinical Study 68 LymphoStat B belimumab 68 Drug Eluting Stent System 68 virus HCV protease inhibitor 68 Histone Deacetylase 68 Omacetaxine 68 By DENES HUSTY 68 Antitumor Activity 68 JZP 68 Kinase Inhibitor 68 NDA Submission 68 TO AVOID PREGNANCY WHILE 68 selective A2A adenosine receptor 68 Vascular Disrupting Agent 68 Desvenlafaxine Succinate 68 selective phosphodiesterase 68 Prolongs Survival 68 adecatumumab MT# 68 investigational protease inhibitor 68 STEALTH C 68 TMC# C# 68 XL# SAR# 68 evaluating tivozanib 68 By JENNIFER LEARN 68 recombinant PSMA vaccine 68 First Patient Enrolled 68 Ozarelix 68 VICTOR E1 68 Rigel R# 68 Patient Enrollment 68 Peginterferon Alfa 2a 68 PHASE III 68 TAXUS ATLAS 68 dasatinib Sprycel ® 68 catheter occlusion 68 Drug Candidate 68 IMPACT IMmunotherapy 68 LymphoStat B TM 68 Safety Tolerability 68 novel nucleoside analog 68 Prostate AdenoCarcinoma Treatment 68 multicenter randomized Phase 68 Placebo Controlled Study 68 Randomized Controlled 68 sapropterin dihydrochloride Phase 67 R lenalidomide 67 Severe Sepsis 67 AN# topical anti 67 evaluating mipomersen 67 Phase 1b clinical trials 67 Tyrosine Kinase Inhibitor 67 phase IIa 67 DUROS 67 FOLFOX6 chemotherapy regimen 67 Randomized controlled 67 diarrhea predominant irritable 67 Sapacitabine 67 inflammatory PDE 67 FDA Approvals 67 Crofelemer budesonide foam 67 Androxal TM 67 TKB# 67 ISTODAX ® 67 multicenter randomized controlled 67 Inhalation Solution 67 IND Application 67 GW# [003] 67 ADVANCE PD 67 Perifosine KRX 67 oral rivaroxaban 67 Systemic Sclerosis 67 Aurora Kinase 67 Demonstrates Significant 67 Adjunctive Therapy 67 Multicenter 67 APF# Phase 67 Patients Treated With 67 formerly LymphoStat B 67 ascending dose 67 topical gel formulation 67 TELINTRA R 67 SinuNase TM 67 Empatic ™ 67 Tezampanel 67 Spectrum Pharmaceuticals Announces 67 refractory chronic lymphocytic 67 Advanced Melanoma 67 Phase Ib IIa 67 Initiates Clinical 67 IIa clinical 67 TMC# [002] 67 galiximab 67 IND Filing 67 Relapsed Multiple Myeloma 67 PRN FDA Approves 67 2A receptor agonist 67 HuMax EGFr 67 GetGoal Phase III 67 pharmacokinetics PK 67 Panzem R NCD 67 PEGylated Fab fragment 67 Achieves Primary Endpoint 67 Controlled Study 67 Subgroup Analysis 67 Demonstrates Sustained 67 Submits NDA 67 ORAL Sync 67 Pharmacokinetics PK 67 Granted Orphan Drug 67 phase IIb 67 Demonstrates Potent 67 Kahalalide F 67 Presents Preclinical Data 67 JAK2 Inhibitor 67 STRIDE PD 67 intravenous recombinant 67 Novel Inhibitor 67 Testosterone MDTS R 67 PRTX 67 multicenter multinational 67 Files Investigational 67 vinorelbine tartrate 67 Phase IIIb clinical 67 double blinded placebo 67 orally administered inhibitor 67 ALN VSP Phase 67 Pharmacodynamic 67 Phase 1b clinical 67 teriflunomide 67 ORENCIA ® 67 phase IIb III 67 Humanized Anti 67 Treatment Naïve 67 comparing alemtuzumab 67 Phase IIb III 67 novel orally inhaled 67 PRECiSE 67 Protease Inhibitor 67 Acute Ischemic Stroke 67 Phase #/#a 67 daily Infergen 67 albiglutide 67 Angiotensin Converting Enzyme 67 Aplidin R 67 IIa Clinical Trial 67 CIMZIA TM certolizumab pegol 67 Peginterferon 67 Liposomal 67 Phase #b/#a trial 67 Anti Tumor 66 novel histone deacetylase 66 GVAX ® 66 Initiates Phase 2b 66 unique alkylating agent 66 MEND CABG 66 Capsules CII 66 EXPLORE Xa 66 Transdermal Patch 66 Sirolimus Eluting 66 preclinical efficacy 66 prucalopride 66 MEND CABG II 66 Archexin 66 Lung Cancer Trial 66 Mg Uk 66 Relapsed Refractory 66 budesonide MMX 66 Treated Patients 66 phase IIb clinical 66 Silodosin 66 azilsartan medoxomil 66 Double Blind Randomized 66 Ophena TM 66 PANVAC VF 66 Randomized Evaluation 66 Previously Treated 66 Phase #b/#a clinical 66 Initiate Phase II 66 Vildagliptin 66 Personalized Immunotherapy 66 prospective randomized placebo 66 Presents Positive 66 HCV RESPOND 2 66 Glatiramer Acetate 66 Begins Dosing 66 Phase III AFFIRM 66 HGS ETR2 66 pralatrexate injection folate analogue 66 Vicriviroc 66 HDAC Inhibitor 66 occlusion PAO 66 Pegylated Liposomal Doxorubicin 66 Oral Cladribine 66 Syncria R 66 Mg Usa 66 phase IIb study 66 Patients Enrolled 66 ORACLE MS 66 Eluting Stent 66 Antiviral Therapy 66 CRMD# 66 Shows Efficacy 66 Novolimus 66 RADIANT 66 vesicular monoamine transporter 66 Shows Statistically Significant 66 Tarceva TM 66 product candidate Lpathomab 66 Complicated Skin 66 Phase Ib study 66 pan histone deacetylase 66 Active Ulcerative Colitis 66 antibody MAb 66 Sipuleucel T 66 Single Dose 66 Is Well Tolerated 66 Intravitreal 66 Recurrent Glioblastoma 66 EOquin TM phase 66 CIMZIA TM 66 Degarelix 66 Romidepsin 66 opioid naive 66 HuMax CD#b 66 CD# [004] 66 Preclinical Data 66 Investigational Compound 66 Treatment Naive Patients 66 Sorafenib HCC Assessment 66 MKC# 66 approved incretin mimetic 66 ENDEAVOR IV 66 alfa 2a 66 CYP#A# CYP#D# 66 multicenter placebo controlled 66 generation purine nucleoside 66 tramiprosate Alzhemed TM 66 Clinical Efficacy 66 Suppl 66 RE LY 66 ABLYNX 66 interferon gamma 1b 66 Ondansetron Injection USP 66 Myocardial Infarction Study 66 PEGylated interferon beta 1a 66 Refractory Hodgkin Lymphoma 66 Interferon Gamma 66 Traficet EN 66 includes TOLAMBA TM 66 oral nucleoside analogue 66 REVIVE Diabetes 66 Immunogenicity 66 induced macular edema 66 AEGR 66 Central Retinal Vein 66 Eszopiclone 66 Oral Calcitonin 66 bowel syndrome IBS 66 Phase III ADT 66 Xyfid TM 66 signal detection CTSD 66 lexidronam injection 66 MKC# MKC# PP 66 vapreotide acetate 66 rALLy clinical trial 66 metaglidasen 66 Xcytrin R 66 TRO# 66 evaluating carfilzomib 66 Randomized Placebo controlled 66 Phase 1a 66 liposomal formulation 66 PROVENGE ® 66 trial evaluating PRX# 66 Brentuximab Vedotin SGN 66 Saxagliptin 66 ACTEMRA TM 66 Prospective Multicenter 66 hypoxia activated prodrug 66 dyskinesia PD LID 66 CAMMS# 66 Phase IIB 66 BENLYSTA ™ 66 Panzem R 66 oral ridaforolimus 66 Dasatinib 66 CALGB # [002] 65 evaluating satraplatin plus 65 Phase 1b 65 Hypertensive Patients 65 protein tyrosine phosphatase 1B 65 trastuzumab DM1 T DM1 65 Shows Promising 65 sunitinib Sutent ® 65 Medoxomil 65 ROCKET AF 65 5 fluorouracil leucovorin 65 Zenvia ™ 65 Clolar ® 65 Orally Active 65 Phase 65 unfractionated heparin UFH 65 midstage clinical 65 somatostatin analog 65 mg q#h 65 ara C 65 ZYBRESTAT TM 65 COR Diabetes 65 relapsed MM 65 Clinical Trials Update 65 randomized controlled multicenter 65 Fulvestrant 65 Oral NKTR 65 mGluR2 positive 65 Phase III confirmatory 65 evaluating T DM1 65 FDA Accepts 65 ARRY # 65 PSN# [002] 65 PEGINTRON TM 65 prospective randomized multicenter 65 generation antisense inhibitor 65 Sirolimus Eluting Stent 65 Potent Antiviral Activity 65 HCV Protease Inhibitor 65 XL# anticancer compounds 65 BY DOUGLAS HANKS 65 Polymerase Inhibitor 65 cetrorelix pamoate 65 Phase III Pivotal Trial 65 CALERIE 65 CYT# potent vascular disrupting 65 FDA APPROVES 65 VEGFR2 inhibitor 65 Anti Tumor Activity 65 Stent Restenosis 65 Janus Kinase 65 Tipranavir 65 mg qd 65 Teva Provides Update 65 alvespimycin 65 Zenvia Phase III 65 Mycophenolate Mofetil 65 includes investigational compounds 65 receptor tyrosine kinase inhibitor 65 ASTEROID 65 Taro Receives 65 MADIT 65 Qutenza TM 65 SPIRIT FIRST 65 Liraglutide Effect 65 Blind Placebo Controlled Trial 65 Acute Attacks 65 oral renin inhibitor 65 Receives Orphan Drug Designation 65 allosteric modulator NAM 65 Metastatic Colorectal Cancer 65 registrational trial 65 TG MV 65 3 registrational trial 65 Sustained Efficacy 65 ALN HPN 65 AEG# 65 Benign Prostatic Hyperplasia 65 Albuferon TM 65 Dose Finding 65 lead Aganocide compound 65 MAGE A3 ASCI 65 lintuzumab SGN 65 BiTE R 65 selective androgen receptor modulator 65 LAB CGRP 65 EOquin TM 65 Oral Insulin 65 2 inhibitor CYT# 65 acyclovir Lauriad R 65 DermaVir Patch 65 mg TID 65 cathepsin K inhibitor 65 CTAP# Injection 65 Novel Compound 65 PEGylated anti 65 PROTECT AF 65 FOLOTYN ® 65 non nucleoside inhibitor 65 BY GUILLERMO 65 REUTERS Claro Cortes 65 NUVIGIL ® 65 comparing XIENCE V 65 colesevelam HCl 65 Initiates Clinical Trial 65 Dose Response 65 gastrin analogue TT 65 Pivotal Clinical Trial 65 Proc Am Soc 65 evaluating Actimmune 65 Randomized Study 65 RELOVAIR ™ 65 multicenter prospective 65 See CLINICAL PHARMACOLOGY 65 Romiplostim 65 stated Michelle Berrey 65 placebo controlled dose escalation 65 HCV Genotype 65 CTAP# Capsules 65 Phase 1b trial 65 2 methoxyestradiol 65 sunitinib malate 65 Contrave# 65 Febuxostat 65 Immunotherapeutic 65 Ceflatonin R 65 Immunomedics Announces 65 PROTEGE 65 agonistic human 65 SUCCEED trial 65 FDA Okays 65 XP# XP# 65 GVAX R 65 Bepreve TM 65 Clinical Outcome 65 retinal vein occlusion induced 65 randomized multicenter trial 65 Oral Insulin Capsule 65 Telaprevir VX 65 multicenter randomized 65 PI3K/Akt pathway inhibitor 65 maximally tolerated dose 65 preclinical pharmacokinetic 65 Chronic Hepatitis C 65 confirmatory Phase 65 Improves Outcomes 65 TM Drug Eluting 65 CG# oncolytic virus 65 Well Tolerated 65 mertansine 65 docetaxel Taxotere R 65 Xeloda ® 65 ChronVac C R 65 Denufosol 65 Empatic TM 65 Receptor Agonist 65 Demonstrate Significant 65 NOX E# 65 cetuximab Erbitux R 65 Cutaneous T 65 RezularTM 65 Recombinant Human 65 Ranolazine 65 Insulin Glargine 65 Hepatitis C Genotype 65 Phase Ib clinical trials 65 IN PATIENTS WITH 65 placebo controlled Phase III 65 Investigational Treatment 65 Preclinical Models 65 Dalbavancin 65 pharmacogenomic translational research 65 PF # [002] 65 Mylan Receives Approval 65 mGluR5 NAM 65 ENDEAVOR III 65 evaluating Xcytrin 65 Phase III Trials 65 Heterozygous Familial Hypercholesterolemia 65 phase 2a 65 RIBBON 64 Custirsen 64 Ecallantide 64 6R BH4 64 Ambrisentan 64 Capesaris 64 elotuzumab 64 Cinacalcet HCl 64 5alpha reductase 64 Efficacy Trial 64 davunetide intranasal AL 64 Dyloject TM 64 placebo controlled clinical 64 DDP# 64 GATTEX TM 64 Cannabinor 64 EQUATE OB 64 Folfox 64 Diabetic Macular Edema DME 64 Plaque Psoriasis 64 XL# XL# XL# 64 Pafuramidine 64 EGFR HER2 64 pan HDAC inhibitor 64 Calcium Acetate 64 SYN# 64 paclitaxel poliglumex 64 Placebo Controlled Trial 64 ORMD 64 Advaxis Phase 64 cannabinor 64 Newly Diagnosed Multiple Myeloma 64 Efficacy Results 64 RhuDex 64 Adalimumab 64 Remission Maintenance 64 Rotavirus Vaccine 64 GATTEX ™ 64 Drug Eluting Coronary Stent 64 Spiegelmer ® 64 gemcitabine Gemzar ® 64 acute peripheral arterial 64 Investigational Drug 64 Patient Enrolment 64 EXECUTIVE SUMMARY 64 anti botulism antibody 64 TASKi2 64 delivery polymer matrix 64 metastatic hormone refractory 64 ADVANCE ILLUMINATE 64 RANK Ligand inhibitor 64 Phase III placebo controlled 64 Clin Oncol 64 DURATION 64 selective estrogen receptor modulator 64 generation Hsp# inhibitor 64 TRANSDUR ™ 64 Multicenter Randomized Double 64 Refractory Angina 64 AVONEX ® 64 dose escalation trial 64 Biomarker Study 64 E1 INT TM 64 azathioprine monotherapy 64 beta 1a 64 PERSEUS 64 Amrubicin 64 oral transmucosal fentanyl citrate 64 Systemic Delivery 64 AASLD Meeting 64 Novel Therapeutic 64 Fast Tracked Phase 64 Tanespimycin 64 Gastrointestinal Stromal Tumors 64 Sanofi Pasteur Fluzone 64 Carfilzomib 64 ASSIGNMENT OF ERROR 64 ALGRX 64 Vitaxin 64 Naproxcinod 64 Aryplase 64 J Clin 64 Telik logo TELINTRA 64 LEVADEX TM 64 omacetaxine mepesuccinate 64 IFN α 64 ASCO Abstract 64 Bezielle 64 evaluating satraplatin 64 polymerase inhibitor 64 Epratuzumab 64 Nilotinib 64 Anticancer Drug 64 CRLX# 64 unresectable stage 64 Receives Approvable Letter 64 solithromycin 64 Clinical Evaluation 64 visilizumab 64 Poster Discussion 64 plus DOXIL 64 Lung Cancer Drug 64 DEB# 64 EGS# 64 DIRECT Trial 64 COPERNICUS 64 Metastatic Renal Cell Carcinoma 64 R roscovitine CDK cyclin 64 CLARITY study 64 Relapsing Remitting Multiple Sclerosis 64 Content Outline 64 Enzastaurin 64 J Natl Cancer Inst 64 SAR# [002] 64 PDUFA Date 64 Anthrax Toxin 64 INSPIRE Trial Phase III 64 Alocrest 64 oral picoplatin 64 Hepatocellular Carcinoma 64 Bipolar Depression 64 Study Showed 64 pharmacokinetic PK 64 Valsartan 64 APPRAISE 64 KRN# 64 AFREZZA TM 64 cromolyn sodium 64 TEMSO 64 Lupus Drug 64 REVIVE TA 64 Abstract Number 64 Linagliptin 64 Tocilizumab 64 Releasing Factor 64 CLARITY TIMI 64 fostamatinib 64 Investigational Agent 64 Antitumor activity 64 Multiple Myeloma MM 64 EDEMA3 64 oral Janus kinase 64 Clinical Study Shows 64 Varespladib 64 Myeloma Patients 64 multicentre phase 64 ONCONASE R 64 riociguat 64 genotype 1a 64 BENLYSTA ® 64 TRAIL R1 64 Diamyd Medical Diamyd 64 XOMA 3AB 64 Vaccine Adjuvant 64 Initiates Clinical Trials 64 J Allergy Clin 64 Quinamed 64 Decitabine 64 Anticancer Activity 64 heFH 64 initiated confirmatory Phase 64 Treatment Experienced 64 Entereg R 64 ECASS 64 demonstrated antitumor activity 64 Ziprasidone 64 Teriflunomide 64 PF # [001] 64 Vitro Activity 64 telomerase therapeutic 64 Dapagliflozin 64 Deforolimus 64 STENT 64 Sandostatin R 64 desvenlafaxine succinate 64 SCH # 64 ZYBRESTAT fosbretabulin 64 neratinib 64 Phase 2a clinical trials 64 MoxDuo ® 64 CTA# Injection 64 Shows Promise Against 64 sulodexide 64 cortisol synthesis 64 Maximum Tolerated Dose MTD 64 tolerability pharmacokinetics 64 Cell Lymphoma 64 class anticancer quinolone 64 investigational humanized monoclonal antibody 64 IMPDH inhibitor 64 Pralatrexate 64 prospective multicenter randomized 64 Fixed Dose 64 Vaccine Adjuvants 64 Podium Presentation 64 BRILINTA 64 Ocrelizumab 64 TELCYTA 64 Present Preclinical Data 64 PREOS R 64 Immunomodulatory 64 candidates Augment ™ 64 Injectable Bone Graft 64 Augment TM 64 Phase Ib 64 Onyx Pharmaceuticals Announces 64 hGH CTP Phase 64 investigational monoclonal antibody 64 Percutaneous Tibial Nerve Stimulation 64 R# #mg BID 64 pregabalin Lyrica 64 Soft Tissue Sarcoma 64 Copegus ribavirin 64 evaluating picoplatin 64 Aeolus Pharmaceuticals Announces 64 dasatinib Sprycel 64 oncolytic virus therapies 64 #-# Full Text 64 Cimzia ® certolizumab pegol 64 GEM OS2 64 Oral Formulation 64 keloid scarring 64 QLT# 64 brivaracetam 64 Anti CD# Antibody 64 stage IIIb 64 systemic juvenile idiopathic 64 AIR CF1 64 Pemetrexed 64 Factor VIIa 64 relapsed refractory multiple myeloma 64 CINQUIL 64 Fast Track Status 64 ENABLE Phase 2 64 #mg QD [002] 64 randomized Phase 2b 64 HGS ETR1 mapatumumab 64 Pharmacokinetic 64 Advanced Renal Cell 64 BENLYSTA TM 64 Fondaparinux 64 Parkinson disease levodopa induced 64 active comparator 64 Gout Drug 64 Myelodysplastic Syndrome MDS 64 ExTRACT TIMI 64 J Am Coll 64 BIBW 64 initiate multicenter 64 Inflammatory Arthritis 64 mg administered orally 64 relapsing multiple sclerosis 64 NS5B polymerase 64 Forodesine 64 PORxin TM platforms 64 abstr 64 Arch Neurol 64 ELACYT 64 dimebon latrepirdine 64 RNAi Therapeutic 64 LibiGel ® 64 REG1 Anticoagulation System 64 Nicotine Vaccine 64 HCV NS5B polymerase 64 Dacogen injection 64 CB2 selective receptor agonist 64 ORAL Solo 64 Initiates Dosing 64 TBC# 64 Demonstrates Efficacy 64 Amigal TM 64 lorcaserin Phase 63 Inhalation Aerosol 63 Trandolapril 63 PSMA ADC 63 PARGLUVA 63 Lupus Nephritis 63 PDE4 inhibitor 63 plus Copegus R 63 alemtuzumab Campath 63 KSP inhibitor 63 Disease Modifying 63 erlotinib Tarceva ® 63 familial amyloidotic polyneuropathy FAP 63 Acute Decompensated Heart Failure 63 PFO migraine 63 AVOREN 63 GAMMAGARD 63 Entereg TM 63 Crit Rev 63 AIR2 Trial 63 ZACTIMA 63 chemotherapy FOLFOX 63 Luteinizing Hormone Releasing Hormone 63 Pharmacodynamics 63 evaluating Prochymal 63 Hydrochlorothiazide Tablets 63 randomized Phase IIb 63 Synta Announces 63 R Saizen R 63 methionine aminopeptidase 63 dosing cohort 63 Posaconazole 63 EINSTEIN DVT 63 ILUVIEN ® 63 mg kg BID 63 HCD# [002] 63 sorafenib Nexavar 63 Long Lesion 63 Glypromate 63 HEPLISAV TM 63 Expanded Indication 63 Phospholipase 63 Anticancer Drugs 63 prospective multicenter 63 Orthostatic Hypotension 63 SinuNase ™ 63 Anturol TM 63 Prospective Randomized Trial 63 ATAC Arimidex Tamoxifen Alone 63 Luveniq 63 Pulmonary Arterial Hypertension 63 Therapeutic Efficacy 63 Randomized Placebo Controlled 63 generation DACH Platinum 63 pain palliation 63 SABCS 63 Cloretazine R VNP#M 63 Prostate Cancer Vaccine 63 lucinactant 63 IL# PE#QQR 63 INS# [001] 63 CD# CEA 63 Vasc 63 Paclitaxel Carboplatin 63 cisplatin gemcitabine 63 Completes Dosing 63 CCX# 63 Iloperidone 63 product platforms AZX# 63 generation PNP inhibitor 63 Medullary Thyroid Cancer 63 EURIDIS 63 Omigard TM omiganan pentahydrochloride 63 R Interferon beta 63 Telik Announces 63 GW MILLER 63 Schizophrenia Treatment 63 Plicera 63 sorafenib tablets 63 Aliskiren 63 AstraZeneca Targacept 63 BENICAR HCT 63 Ann Rheum Dis 63 Dose Escalation Study 63 MEVACOR 63 DASISION 63 Randomized Controlled Trials 63 EVEREST II